The stock of Adial Pharmaceuticals Inc (ADIL) has seen a 1.05% increase in the past week, with a -11.11% drop in the past month, and a -11.93% decrease in the past quarter. The volatility ratio for the week is 4.58%, and the volatility levels for the past 30 days are at 4.19% for ADIL. The simple moving average for the last 20 days is -2.72% for ADIL stock, with a simple moving average of -27.31% for the last 200 days.
Is It Worth Investing in Adial Pharmaceuticals Inc (NASDAQ: ADIL) Right Now?
The 36-month beta value for ADIL is at 1.30. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADIL is 6.29M, and currently, shorts hold a 1.24% of that float. The average trading volume for ADIL on October 17, 2024 was 2.70M shares.
ADIL) stock’s latest price update
Adial Pharmaceuticals Inc (NASDAQ: ADIL)’s stock price has decreased by -6.80 compared to its previous closing price of 1.03. However, the company has seen a 1.05% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-19 that GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced database lock for the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day).
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Maxim Group repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Maxim Group is $5 based on the research report published on October 30, 2018 of the previous year 2018.
ADIL Trading at -4.24% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.98% of loss for the given period.
Volatility was left at 4.19%, however, over the last 30 days, the volatility rate increased by 4.58%, as shares sank -9.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.11% lower at present.
During the last 5 trading sessions, ADIL rose by +0.04%, which changed the moving average for the period of 200-days by -45.69% in comparison to the 20-day moving average, which settled at $0.9864. In addition, Adial Pharmaceuticals Inc saw -48.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ADIL
Current profitability levels for the company are sitting at:
- -225.58 for the present operating margin
- 0.98 for the gross margin
The net margin for Adial Pharmaceuticals Inc stands at -379.59. The total capital return value is set at -1.7. Equity return is now at value -320.96, with -279.27 for asset returns.
Currently, EBITDA for the company is -6.89 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 89.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.69.
Conclusion
In conclusion, Adial Pharmaceuticals Inc (ADIL) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
